Electra (ETRA) CSO Parry Graham Converts 85,504 Shares

What Happened

• Parry Graham, Chief Scientific Officer of Electra Therapeutics (ETRA), converted derivative securities into 85,504 shares of common stock on 2026-09-21. The conversion was automatic upon the closing of the issuer's initial public offering and required no cash payment (price listed as N/A).
• The filing shows the corresponding disposition of the derivative instrument (the embedded preferred/share conversion) and the acquisition of the underlying common shares — in plain terms, previously-held Series A Convertible Preferred Stock converted into common stock. No open-market purchase or sale occurred.

Key Details

• Transaction date: 2026-09-21 (filing also dated 2026-09-21) — filing appears timely.
• Shares involved: 85,504 common shares acquired via conversion; corresponding derivative interest disposed.
• Price/consideration: N/A — conversion occurred automatically upon IPO closing, per footnote.
• Shares owned after transaction: not specified in the supplied filing text.
• Notable footnotes:
  • F1: 7,125 of the shares are labeled "Restricted Shares" and are subject to a vesting schedule (footnote text: "1/4th of the Restricted Shares shall vest monthly commencing from September 2, 2026").
  • F2: Each share of Series A Convertible Preferred Stock converted automatically into 1 share of common stock upon the IPO closing, without further consideration; the Preferred Stock had no expiration date.

Context

• This was a conversion of preferred/derivative securities into common stock tied to the company’s IPO completion — not an open-market buy or sale. Such conversions reflect capitalization changes after an IPO rather than a direct insider trade intended to express bullish or bearish sentiment.
• For retail investors, the key takeaways are the size of the conversion (85,504 shares) and the existence of 7,125 restricted shares that will vest over time per the footnote.